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ABSTRACT 
 
EFFECTS OF QUERCETIN SUPPLEMENTATION ON INNATE IMMUNE FUNCTION 
AND INFLAMMATION IN FEMALE HUMAN SUBJECTS 
(May 2010) 
Serena Ann Heinz, B.S., Appalachian State University 
M.S., Appalachian State University 
Thesis Chairperson: Dru A. Henson, Ph.D. 
  
PURPOSE: Quercetin, a flavonoid found in fruits and vegetables, is a strong antioxidant 
with anti-inflammatory, antimicrobial, and immune-modulating properties. The purpose of 
this study was to investigate the effects of long-term quercetin supplementation on innate 
immune function and inflammation in human subjects.  
STUDY DESIGN: Female subjects (N=120, ages 30-79 years) were recruited from the 
community and randomized to one of three groups, with supplements administered using 
double-blinded procedures: Q-500 (500 mg/day quercetin, N=38), Q-1000 (1000 mg/day 
quercetin, N=40), or placebo (N=42). Subjects ingested two soft chew supplements twice 
daily during the twelve-week study period. Fasting blood samples were obtained pre- and 
post-study and were analyzed for plasma quercetin, interleukin (IL)-6, tumor necrosis factor 
(TNF)-α, and leukocyte subset cell counts. Natural killer cell activity (NKCA) and 
lymphocyte subsets were assessed on a subset of seventy-four subjects. Granulocyte 
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oxidative burst activity (GOBA) and phagocytosis were assessed on sixty-four subjects. 
Eighteen subjects had overlapping data.  
RESULTS: Quercetin supplementation at 500 and 1000 mg/day increased plasma quercetin 
(interaction effect, P<0.001) compared to placebo but had no significant influence on blood 
leukocyte or lymphocyte subset concentration, plasma IL-6 or TNF-α concentration, NKCA, 
GOBA, or granulocyte phagocytosis. NKCA was inversely correlated with BMI (r=-0.25, 
P=0.035) and body fat percentage (r=-0.38, P=0.001), and positively correlated with self-
reported physical fitness level (r=0.24, P=0.032).  
CONCLUSIONS: Results from this double-blinded, placebo-controlled, randomized trial 
indicate that quercetin supplementation at 500 and 1000 mg/day for twelve weeks 
significantly increased plasma quercetin levels but had no influence on measures of innate 
immune function or inflammation in community-dwelling adult females. 
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INTRODUCTION 
   
 Polyphenolic compounds are found in a wide variety of human foods, including 
fruits, vegetables, nuts, seeds, flowers, tea, and honey (1). Flavonoids are a large and 
complex group of polyphenols that share a basic three-ring chemical structure, with two 
aromatic centers and a central oxygenated heterocyclic ring (2). The most prominent 
flavonoids in fruits and vegetables are flavonols, and of these, quercetin (3,3’,4’,5,7-
pentahydroxyflavone) is the most commonly consumed in the human diet (2). Total dietary 
flavonol intake estimates for US adults range from 13 to 22 mg/day, with quercetin 
representing about 75% (3, 4).  
 Following absorption from food or supplements, elimination of quercetin is slow, 
with a reported half-life ranging from 11 to 28 hours (2). Quercetin conjugates are widely 
distributed in the organ tissues of rats after supplementation, where they may be biologically 
active (5). The physiologic effects of quercetin and other dietary flavonols are of relevance to 
human health because of their anti-oxidative (6, 7), anti-inflammatory (8, 9), and anti-
pathogenic (10, 11) properties. The present study focuses on the potential beneficial health 
effects of supplementation with quercetin with regard to inflammation and innate immune 
function. 
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Inflammation 
 The human body reacts defensively to pathogenic invasion with an inflammatory 
response characterized by pain, redness, heat and swelling. Blood vessels dilate at the site of 
infection, resulting in localized swelling and the accumulation of defensive blood proteins 
and complement components, while endothelial cells lining the nearby blood vessels are 
stimulated to express cell adhesion molecules that facilitate the attachment and extravasation 
of white blood cells such as lymphocytes and monocytes (12). This inflammatory response is 
mediated by various signaling molecules, including prostaglandins and cytokines. Some 
cytokines function as chemoattractants (chemokines) that recruit white blood cells to the site 
of an infection; other cytokines trigger a fever that simultaneously inhibits pathogenic 
activity and optimizes conditions for host defense (12). 
 While highly effective against acute infections, inflammatory responses can result in 
disease states if the inflammation is inappropriate, excessive or chronic. For example, pro-
inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor (TNF)-α, and IL-6 
are known to play critical roles in the development of rheumatoid arthritis via their 
inflammatory effects on endothelial cells in synovial tissue (13). Chronically elevated levels 
of the inflammatory marker C-reactive protein (CRP) and the pro-inflammatory cytokine IL-
6 have been strongly correlated with increased risk of coronary heart disease (14-16). 
Because of the potentially deleterious effects of chronic inflammation, the discovery of 
dietary supplements that could mitigate chronic inflammatory conditions and reduce risk 
factors for debilitating illnesses is of great current interest.  
 The advantage of using flavonoids to control inflammation lies in their safety and 
potential for providing other health benefits with long-term use. Contrary to earlier concerns 
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regarding quercetin’s potential in vivo genotoxicity, high-dose supplementation with 
quercetin (acute dosages of up to 2000 mg/kg body weight and long-term doses of up to 500 
mg/kg for two years) has been shown to lack a mutagenic or genotoxic effect in rodents (17, 
18). Furthermore, epidemiological studies have correlated numerous health benefits with 
regular flavonoid consumption by humans, including decreased incidence of coronary heart 
disease (19), decreased risk of common human cancers (20), and lowered markers of 
inflammation (21-24). 
 
Innate immune function 
 In vitro and animal studies also indicate that quercetin supplementation has the 
potential to exhibit multiple immunomodulatory effects including augmentation of neutrophil 
chemotaxis and oxidative burst activity (25), macrophage function (26, 27), and natural killer 
cell lytic activity (27, 28). Natural killer (NK) cells and neutrophils are dominant players in 
early host defense against pathogens, and their potential augmentation by quercetin could 
have important health benefits.  
 NK cells, which comprise 10-15% of circulating lymphocytes in humans, play a 
central role in initial host resistance to viral, bacterial, and parasitic infections due to their 
ability to kill target cells without prior sensitization (29, 30). NK cells express both activating 
and inhibitory receptors on their surfaces, and the killing of potential target cells by NK cells 
depends on the balance between activating and inhibitory signals. Granules containing 
granzymes and perforin are released into the immunological synapse between an NK cells 
and its potential target only if the activation signal dominates. When inhibitory receptors 
such as killer Ig-like receptors (KIRs) bind to the MHC class I proteins on the potential 
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target, molecules involved in the NK cell activation pathway are dephosphorylated (31). 
Thus, if an NK cell encounters a cell expressing normal levels of MHC class I proteins on its 
surface, the binding of inhibitory receptors leads to intracellular events that override the 
activation signal and the granules are not released. Because transformed and infected cells 
often have low MHC class I expression, they are vulnerable to attack by NK cells. The 
importance of NK cells to host defense against pathogens is underscored by the increased 
susceptibility to repeat infections experienced by patients with NK cell deficiency conditions 
(32). 
 Also critical to optimal cellular immune function are the phagocytic and microbicidal 
activities of polymorphonuclear leukocytes, or neutrophils, which comprise 50-70% of white 
blood cells (33). Neutrophils are granulocytes that migrate along chemoattractant gradients to 
infection sites, where they engulf pathogens via phagocytosis. Pathogens thus ingested by 
phagocytes can be killed through oxygen-dependent or oxygen-independent mechanisms. In 
the oxygen-dependent pathway, NADPH oxidase complexes on the phagolysosomal 
membrane catalyze the oxidation of cytosolic NADPH, a reaction which is coupled to the 
reduction of oxygen molecules in the phagolysosome (33). The resultant superoxide anions 
are dismutated by superoxide dismutase (SOD) to form hydrogen peroxide (H2O2), which 
generates other reactive oxygen species such as hypochloride (ClO
-
), hydroxyl radicals 
(OH·), and singlet oxygen (·O2). These highly toxic compounds are responsible for the 
oxygen-dependent killing of phagocytosed microbes, and their production causes a transient 
increase in oxygen consumption by the phagocyte, commonly referred to as the respiratory or 
oxidative burst.  
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 Quercetin, which has been shown in animal and in vitro studies to augment NK cell 
cytolytic activity and neutrophil function (25, 27, 28), could potentially be taken as a 
supplement to improve innate immune function, thereby reducing risk of illness.  
 
Previous work 
 Numerous in vitro studies that have examined the effects of quercetin on pro-
inflammatory cytokine production in a wide variety of cells have shown that quercetin exerts 
strong anti-inflammatory effects via suppression of nuclear factor-kappa B (NF-κB) 
activation (9, 34, 35). Homo- and hetero-dimers of NF-κB transcription factors are located in 
the cytoplasm of unstimulated immune cells, where they are tightly bound to IκB inhibitory 
proteins (9). When immune cells are stimulated, the IκB proteins are phosphorylated, 
ubiquitylated, and degraded, freeing the NF-κB dimers for translocation to the nucleus, 
where they bind to the promoter regions of genes involved in the inflammatory response. 
Inhibition of IκB phosphorylation represents one mechanism by which quercetin could 
suppress the expression of numerous inflammatory cytokines. 
 Cho et al. (34) used RAW 264.7 cells, a line of murine macrophages, to study 
quercetin’s anti-inflammatory actions. Macrophages are white blood cells that are important 
mediators of inflammatory response due to their production of cytokines and nitric oxide 
(NO) following stimulation by an endotoxin expressed on the cell walls of Gram-negative 
bacteria, lipopolysaccharide (LPS). Cho et al. found that nitrate generation, iNOS mRNA 
production, and iNOS protein expression were inhibited by quercetin in a dose-dependent 
manner, as were TNF-α, IL-1β, and IL-6 mRNA production. Their results indicated that 
incubation with quercetin inhibited the phosphorylation of ERK and p38 MAPK and also 
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inhibited the phosphorylation and degradation of IκBα, thereby stabilizing the NF-κB/IκB 
complex and suppressing the activation of NF-κB. 
 Similar experiments were performed by Nair et al. (9) and Min et al. (35). Nair et al. 
(9) studied TNF-α production and regulation in peripheral blood mononuclear cells 
(PBMCs), which are agranular immune cells that include lymphocytes (B cells, T cells, and 
NK cells) and monocytes. Their results indicated that in vitro quercetin treatment down-
regulated expression of TNF-α and NF-κB mRNA, suppressed exogenous and induced TNF-
α production in PBMCs, and inhibited the activation of NF-κB via suppression of IκBα and 
IκBβ phosphorylation. Min et al. (35) examined quercetin’s effects on pro-inflammatory 
cytokine expression in the human mast cell line, HMC-1. Mast cells are key mediators of 
allergic inflammatory responses. Once activated, mast cells produce numerous chemotactic 
and pro-inflammatory cytokines, including IL-6 and TNF-α. Min et al. found that quercetin 
treatment decreased TNF-α, IL-1β, IL-6, and IL-8 gene expression and production in 
stimulated mast cells via the inhibition of NF-κB and p38 MAPK activation.  
 As described above, quercetin has been shown to exert in vitro anti-inflammatory 
effects through inhibition of IκB phosphorylation and the consequent suppression of NF-κB 
activation. Binding sites for NF-κB proteins have been found in the promoter regions of the 
genes that code for both TNF-α and IL-6, and studies have shown that IL-6 mRNA 
production does not occur in the absence of activated NF-κB (36, 37). It might be expected, 
therefore, that quercetin supplementation would decrease circulating levels of IL-6 and TNF-
α. However, most of the existing data regarding quercetin’s anti-inflammatory properties 
have come from in vitro study designs, and relatively few in vivo studies have been 
performed. 
 
7 
 
 Choi et al. (38) fed mice either vitamin E-deficient or control diets for nine weeks and 
supplemented subgroups of the mice with 0.5% quercetin. After four weeks, they induced 
arthritis in the animals by immunization with collagen. Choi et al. found that the increase in 
joint tissue TNF-α and IL-1β mRNA expression associated with the vitamin-E deficient diet 
was reduced to control levels in the quercetin-supplemented group at nine weeks; however, 
no differences in cytokine mRNA expression were found between the quercetin-
supplemented and control mice on a normal diet. Mamani-Matsuda et al. (39) found that oral 
supplementation with quercetin (30 mg every two days) for ten days significantly reduced 
clinical signs of arthritis in adjuvant-induced arthritic Lewis rats, and showed that quercetin 
inhibited murine macrophage activation and TNF-α production ex vivo and in vitro.  
Stewart et al. (40) fed C57BL/6J mice a high-fat diet with or without 0.8% quercetin 
(approximately 0.8 mg/gram body weight per day) and found that circulating markers of 
inflammation INF-γ, IL-1α, and IL-4 were significantly lower in the quercetin-fed mice 
compared to controls after eight weeks. These changes in inflammatory status were 
independent of adiposity, which was itself unaffected by quercetin consumption, suggesting 
that quercetin supplementation might be used to mitigate the chronic low-grade inflammation 
associated with obesity.  
Few studies have examined the effects of quercetin supplementation on chronic 
inflammation in humans, however. A recent study by Egert et al. investigated whether 150 
mg/day quercetin for six weeks would decrease plasma TNF-α in overweight and obese 
subjects (BMI 25-35 kg/m
2
), but no such effect was found (41). The authors postulated that 
the dosage of quercetin used in their study was insufficient to exert significant anti-
inflammatory effects in the blood compartment. Beyond this, the limited human studies to 
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date have largely focused on the acute effects of quercetin in athletes following exercise 
stress. Longer-term supplementation studies are needed to assess the effects of quercetin 
consumption on circulating markers of inflammation. 
 As with inflammation, the body of evidence indicating that quercetin augments innate 
immunity including natural killer cell and neutrophil function is comprised primarily of data 
from animal and in vitro studies (25, 27, 28). Exon et al. (28) showed that rats fed 100 mg/kg 
quercetin dihydrate daily for seven weeks had significantly elevated natural killer cell 
activity (NKCA) compared to controls. This was in contrast to their in vitro results, which 
showed that splenic NK cells exposed to quercetin had decreased cytotoxicity (28). Exon et 
al. postulated that this discrepancy could be due to an indirect enhancement of NKCA by 
quercetin in vivo, perhaps through enhancement of interferon (IFN) effects. Quercetin has 
been shown to upregulate IFN-γ gene expression and production when cultured with PBMCs 
at concentrations from 10-50 μM (42). IFN-γ, in turn, regulates NK cell function (43) and 
may mediate the potential immunostimulatory properties of quercetin in vivo. 
 A recent study by Yu et al. (27) found that the cytotoxic activity of NK cells was 
increased in BALB/c mice treated with 2 and 4 mg/kg quercetin daily for three weeks 
following injection with WEHI-3 leukemia cells compared to mice that did not receive 
quercetin. The phagocytic activity of peritoneal macrophages was also increased in mice 
treated with 2 mg/kg quercetin compared to the untreated group, but macrophages isolated 
from peripheral blood did not show a similar response to quercetin. Akbay et al. (25) found 
that incubation with a quercetin glycoside (quercetin-3-O-rutinoside) increased the oxidative 
burst activity of human neutrophils in vitro, with maximum ROS production measured in 
neutrophils that were incubated with 4μg/mL. These studies indicate that quercetin may exert 
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immunomodulatory effects through the enhancement of NKCA and granulocyte oxidative 
burst activity (GOBA). 
 Although these in vitro and animal studies have yielded promising results with regard 
to quercetin’s potential effects on innate immune function and inflammation, previous human 
studies have been limited. The majority of quercetin supplementation trials to date have been 
short-term studies focused on quercetin’s acute effects on post-exercise inflammatory and 
immune function perturbations in athletes.  
 Acute heavy exertion is known to cause temporary changes in host immunity due to 
its suppression of NK cell function, T and B cell activity, and granulocyte oxidative burst 
activity (44).  Prolonged high-intensity exercise is also correlated with increased plasma 
concentrations of pro- and anti-inflammatory cytokines. The period of impaired immunity 
after intense exercise results in an “open window” during which an athlete is more 
susceptible to infection by viral and bacterial pathogens. Much of the research on quercetin 
to date has focused on its effects on subjects following heavy exertion to determine whether 
quercetin exhibits immunoprotective properties that might counter this post-exercise increase 
in illness susceptibility.  
Davis et al. (45) investigated the effects of quercetin on infection rates in mice using a 
viral-challenge study design. The data from this study indicated that 12.5 mg/kg quercetin 
feedings for seven days prior to inoculation with an LD50 dose of A/Puerto Rico/8/34 
(H1N1) influenza virus significantly reduced the increase in morbidity, symptom severity, 
and mortality in mice exercised to exhaustion for three consecutive days. This was the first in 
vivo experiment to provide evidence for the immunoprotective effects of quercetin ingestion 
in a placebo-controlled viral challenge model. However, the Davis et al. study did not 
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examine measures of immune function, so it was unclear whether this effect was due to direct 
anti-viral activities or to augmentation of immune function by quercetin.  
A double-blind placebo-controlled study of forty trained cyclists previously 
performed in our lab found that supplementation with 1000 mg/day aglycone quercetin for 
three weeks before, during, and two weeks after a three-day period of intense exercise 
significantly reduced incidence of self-reported upper respiratory tract infection (URTI) 
following the exercise period (46). In this study, measures of immune function such as 
inflammatory markers, NKCA, and GOBA were examined, but were not found to be altered 
by short-term quercetin supplementation. Another study in trained cyclists found that 
supplementation with 1000 mg/day quercetin for three weeks before and during a three-day 
period of intensified training attenuated the post-exercise increase in leukocyte IL-8 and IL-
10 mRNA expression compared to placebo, providing evidence for immune-modulating 
effects of quercetin through suppression of cytokine gene expression in vivo (47). Another 
short-term quercetin supplementation study in human athletes found that three weeks 
supplementation with 1000 mg/day quercetin did not offset the post-exercise decrease in 
GOBA experienced by runners who completed a 160-km ultramarathon; nor was quercetin 
supplementation effective at counteracting exercise-induced perturbations in leukocyte subset 
counts (48). However, it should be noted that plasma quercetin levels in the experimental 
group dropped significantly over the 20 to 30 hours it took for the athletes to complete the 
race; it is unknown whether consistently-maintained high plasma quercetin concentrations 
could have attenuated the immune perturbations experienced by these ultramarathon runners. 
 In summary, most of the existing evidence supporting quercetin’s anti-inflammatory 
and immunomodulatory properties has come from in vitro and animal studies. Furthermore, 
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in vivo data regarding the effects of quercetin on human subjects have primarily come from 
short-term studies focused on quercetin’s acute effects on post-exercise immune function 
perturbations in highly-trained athletes, and as such are limited in their application to non-
athletes. It is currently unknown whether long-term quercetin supplementation could have 
beneficial health effects in member of the general community. 
 
Purpose of study 
 The present study will examine the chronic effects of quercetin consumption on 
innate immune function and inflammation in female subjects recruited from the general 
population. It is currently unknown whether long-term quercetin supplementation exhibits an 
immunomodulatory effect in humans, or whether these potential effects are dose-dependent. 
The objective of this study was to measure the influence of twelve-week quercetin 
supplementation in two doses (500 and 1000 mg/day) on measures of innate immune 
function (NKCA, GOBA, and granulocyte phagocytosis) and markers of inflammation 
(plasma IL-6 and TNF-α) in middle-aged, community-dwelling female subjects. Dosages and 
supplementation periods used were chosen based on animal studies and prior work in our 
laboratory (47, 49). 
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METHODS 
 
Subjects 
 One hundred twenty females, 30-79 years of age, were recruited via mass advertising. 
Subjects had to be healthy and noninstitutionalized, and women were excluded if pregnant or 
lactating. Subjects agreed to avoid any other supplements containing quercetin; no other 
restrictions were placed on diet, supplement usage, or medications. This study was conducted 
according to the guidelines laid down in the Declaration of Helsinki and all procedures 
involving human subjects were approved by the institutional review board of Appalachian 
State University. Written informed consent was obtained from all subjects. 
 
Research design 
 Subjects were randomized to one of three groups: Q-500 (500 mg/day quercetin, 
N=38), Q-1000 (1000 mg/day quercetin, N=40), or placebo (N=42).  Supplements were 
administered utilizing double blinded procedures. Subjects ingested two soft chew 
supplements twice daily (upon awakening, and between 14:00 hours and the last meal of the 
day) during the twelve-week study period. Supplements were prepared by Nutravail 
Technologies (Chantilly, VA USA) with Quercegen Pharma (Newton, MA USA), and were 
soft, individually-wrapped chews (5.3 g/piece) that contained either 125 or 250 mg quercetin, 
125 or 250 mg vitamin C (ascorbic acid and sodium ascorbate), 5 or 10 mg niacin, and 20 
kilocalories of sugars in a carnauba wax, soy lecithin, corn starch, glycerine, and palm oil 
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base colored with FD&C yellow #5 and #6. A series of HPLC measurements was conducted 
to determine that the amount of quercetin in each chew was stable and accurate. Placebo 
supplements were prepared in the same way minus the quercetin, vitamin C, and niacin. Data 
from Quercegen Pharma indicate that bioavailability of quercetin is enhanced with vitamin C 
and niacin; hence, this study tested whether or not soft chews with or without the 
combination of quercetin, vitamin C, and niacin had an influence on the outcome measures. 
Subjects started supplementing after the first blood sample and continued for twelve weeks. 
Two weeks prior to the first lab visit for the study, subjects provided demographic and 
lifestyle habit information via a survey posted on the web using SurveyMonkey.com 
(Portland, OR USA). Information on dietary patterns was obtained through a semi-
quantitative food frequency questionnaire for food groups including fruit, vegetables, cereals, 
meat, dairy, and fat. Exercise habits were assessed through answers to categorical questions 
dealing with both leisure-time and work activities. Physical fitness levels were self-reported 
using a ten-point Likert scale, with one corresponding to low fitness and ten to high fitness. 
Subject height was measured with a stadiometer, and BMI and body composition were 
determined using a Tanita bioelectrical impedance scale (Tanita, Arlington Heights, IL 
USA). Before and after the twelve-week supplementation period, subjects came to the lab in 
the morning (7:00 - 9:00 hours) after an overnight fast to donate blood samples. Blood 
samples were taken from an antecubital vein with subjects in a seated position. Plasma 
quercetin levels and leukocyte subset cell counts were analyzed for all samples. NKCA and 
lymphocyte subsets were analyzed for seventy-four subjects, and GOBA and phagocytosis 
were assessed on sixty-four subjects. There was some overlap between the cohorts: eighteen 
subjects were tested for both NKCA and GOBA/phagocytosis. 
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Plasma quercetin 
 Total plasma quercetin (quercetin and its primary metabolites) was measured 
following solid-phase extraction via reversed-phase HPLC with UV detection as previously 
described (50, 51). Quercetin conjugates were hydrolyzed by incubating 500 µl plasma 
aliquots with 10 µl 10% DL-Dithiothreitol solution, 50 µl 0.58 M acetic acid, 50 µl of a 
mixture of β-glucuronidase/arylsulfatase and crude extract from Helix pomatia (Roche 
Diagnostics Corporation, Indianapolis, IN USA) for 2 hours at 37°C. Chromatographic 
analysis was performed using the Ultimate 3000 HPLC-PDA system (Dionex Corporation, 
Sunnyvale, CA USA) with a Gemini C18 column (Phenomenex, Torrance, CA USA). Three 
quality control samples, using human plasma samples spiked with quercetin at concentrations 
of 1.0, 1.5, and 3.0 µmol/l, were assayed in duplicate, with an intra-assay coefficient of 
variation (CV) of 12.5%. 
 
Leukocyte differential 
 A complete blood count (CBC) with leukocyte differential was analyzed in the 
clinical lab of the Watauga Medical Center (Boone, NC USA) using standard clinical 
laboratory equipment and quality standards.  
 
Plasma IL-6 and TNF-α 
 High-sensitivity enzyme-linked immunosorbent assay kits were used to measure total 
plasma concentrations of IL-6 and TNF-α in accordance with manufacturer protocol (R&D 
Systems, Inc., Minneapolis, MN USA). All samples and provided standards were analyzed in 
duplicate. The minimum detectable concentrations of IL-6 and TNF-α were <0.039 pg/ml 
 
15 
 
and <0.106 pg/ml, respectively. Pre- and post-supplementation samples were analyzed on the 
same assay plate to decrease interkit assay variability, and the intra-assay CV for all variables 
was less than 10%. Data were analyzed with SOFTmax software (Molecular Devices, 
Sunnyvale, CA USA).  
 
GOBA and phagocytosis 
 Simultaneous measurement of granulocyte oxidative burst activity and phagocytosis 
was performed using a modified flow cytometric assay (52). For each sample, 100 µl 
heparinized whole blood was dispensed into two 15 x 75 mm (5-ml) tubes. To each tube, 10 
µl hydroethidine (HE) working solution (10 µg/ml HE in PBS-glucose; Invitrogen 
Corporation, Carlsbad, CA USA) was added. The tubes were vortexed briefly, incubated in a 
37ºC water bath for 15 minutes, and cooled in a 4 ºC ice-water bath for 12 minutes. After the 
HE-loaded blood samples were cooled, 20 µl of working bacteria-FITC solution 
(Staphylococcus aureus labeled with FITC, diluted in PBS to 1.33 x 10
8
 particles/ml; 
Invitrogen Corporation, Carlsbad, CA USA) was added to both tubes and vortexed briefly. 
Tube 2 (test) was transferred to a 37ºC water bath, and tube 1 (control) was left in the ice. 
The tubes were incubated for 20 minutes, placed in an ice water bath, and 100 µl ice-cold 
Quench Solution (0.025% Trypan blue in 0.1 M Citrate buffer, pH 4.0) was added to each 
tube. The tubes were vortexed for 10 seconds and incubated for 1 minute to quench the FITC 
fluorescence of any non-internalized bacteria, after which the cells were washed twice with 
ice-cold PBS and resuspended in 50 µl cold fetal bovine serum. Samples were processed on a 
Q-Prep™ Workstation (Beckman Coulter, Inc., Fullerton, CA USA), which lysed the 
erythrocytes and stabilized and fixed the white blood cells. Tubes were stored at room 
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temperature in the dark until flow cytometric analysis, which was performed within 24 hours 
of blood collection for all samples.  
 Analysis of samples was performed using a Beckman Coulter FC-500 flow cytometer 
with CXP software (Fullerton, CA USA). FITC emits a green fluorescence that can be 
detected on fluorescence channel 1 (FL1); therefore, cells that phagocytose the FITC-labeled 
bacteria are FL1-positive, and the strength of the fluorescent signal detected on that channel 
is proportionate to the number of bacteria that have been phagocytosed by the cells. 
Similarly, cells thus stimulated by the bacteria will undergo an oxidative burst, oxidizing the 
non-fluorescent HE to ethidium bromide, which emits a red fluorescence that can be detected 
on fluorescence channel 3 (FL3). After gating on the granulocyte cell population 
(predominantly comprised of neutrophils) using forward scatter and side scatter, the mean 
fluorescence intensity (x-mean) for each channel was determined and shifts in x-mean were 
calculated by subtracting the control (4°C) x-mean from the test (37°C) x-mean for FL1 and 
FL3. Typically, 5000 granulocytes were counted for each reaction tube. The mean intra-assay 
CV was <7% for phagocytosis and <10.5% for GOBA.   
 
Lymphocyte subsets 
 Lymphocyte subset data (%NK, %B, and %T) was also obtained by flow cytometry. 
Briefly, peripheral blood mononuclear cells (PBMC) were isolated from heparinized whole 
blood by density gradient centrifugation with Fico/Lite. The cells were washed twice and 
resuspended to 1 ml in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, 
penicillin, streptomycin, and L-glutamine (complete-RPMI). A sample (100 µl) of cells was 
removed and stained for 15 minutes with 10 µl CYTO-STAT® tetraCHROME™ CD45-
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FITC/CD56-RD1/CD19-ECD/CD3-PC5 monoclonal antibody reagent (Beckman Coulter, 
Fullerton, CA USA). CYTOSTAT® tetraCHROME™ is a combination of four murine 
monoclonal antibodies, each conjugated to a specific fluorochrome, used to differentiate 
lymphocyte subsets based on their cell surface markers. The lymphocytes were gated using 
intracellular complexity (side scatter) and FITC fluorescence intensity (CD45+), and flow 
cytometric dot plots of CD19-ECD vs. CD3-PC5 and CD56-PE vs. CD3-PC5 were produced. 
In this manner, the percentage of lymphocytes that were NK cells (CD56+ CD3-), B-cells 
(CD19+ CD3-), and T-cells (CD3+ CD19-) was determined for each subject. Absolute 
numbers of each cell type were then calculated using the CBC data to allow group 
comparison of circulating cell counts. 
 
NK cell activity 
 NK cell cytotoxic activity was assessed using a modification of a flow cytometric 
assay (46, 53). PBMC (effector cells) were isolated from heparinized blood by density 
gradient centrifugation with Fico/Lite, washed twice, and resuspended to 3.75 x 10
6
 cells/ml. 
K562 cells in log phase (target cells, 1 x 10
6
 cells/ml) were labeled for 20 minutes at 37°C in 
5% CO2 with 10 µl 3 mM DiO solution [3,3’-dioctadecyloxacarbocyanine perchlorate (DiO; 
Sigma Chemical Co., St. Louis, MO USA) in DMSO] per 1 ml cell suspension. After 
labeling, the target cells were washed and resuspended in complete-RPMI to a concentration 
of 5 x 10
5
 cells/ml. Effector and target cells were combined in four 15 x 75 mm (5-ml) tubes 
to yield effector:target (E:T) ratios of 60:1, 30:1, 15:1, and 7.5:1 with final volumes of 0.9 
ml. Given the proven reproducibility, high sensitivity, and large number of cells used in this 
flow cytometric assay, a single assay tube was used for each E:T ratio (53). Control tubes 
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received target cells with no effectors. All tubes received 0.1 ml of a 500 µg/ml solution of 
propidium iodide (PI; Sigma Chemical Co., St. Louis, MO USA) in RPMI, after which the 
tubes were vortexed, pelleted by centrifugation for 2 minutes at 1200 rpm, and incubated for 
2 hours at 37°C in 5% CO2. Following incubation, the tubes were vortexed briefly, placed in 
an ice-water bath, and analyzed by flow cytometry within 45 minutes.  
 Analyses of samples were performed using a Beckman Coulter FC-500 flow 
cytometer with CXP software (Fullerton, CA USA). DiO-labeled target cells emit a green 
fluorescence that can be detected on FL1 and compromised cells that have taken up PI emit a 
red fluorescence that can be detected on FL3. The percentage of target cells that were 
compromised was determined for each tube. The results were acceptable if the spontaneous 
lysis of target cells (percent non-viable target cells in the control tube) was less than 5%. NK 
cell-induced killing of target cells was determined by subtracting the spontaneous lysis of 
target cells from the percent non-viable target cells in tubes containing both effectors and 
targets at each E:T ratio. Results were normalized by conversion to lytic units, calculated as 
the number of effector cells required to kill 20% of 5000 target cells, and reported as the 
number of lytic units contained in 10
7
 cells (54).  
 
Statistical analysis 
 All statistical analyses were performed using SPSS PC v.16.0 software (SPSS Inc., 
Chicago, IL USA). Data are expressed as mean ± SEM. Data were analyzed using a 3 
(group) x 2 (time) repeated measures ANOVA, between groups design, with post-hoc 
analysis using independent t-tests that contrasted pre-to-post-supplementation changes of Q-
500 and Q-1000 with placebo. Self-reported fitness levels, BMI, body composition and 
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lifestyle data were correlated with NKCA using Pearson correlations. Subject characteristics 
were contrasted between groups using one-way ANOVA. For all tests, P<0.05 was 
considered significant.
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RESULTS 
 
Subject characteristics 
 Subjects were Caucasian females, ranging in age from 30 to 79 years, with a large 
variance in body mass and composition (Table 1). No changes in body mass and composition 
were noted over the course of the study and interaction effects indicated no group 
differences. With all subjects combined, no significant correlations were found between 
subject age and any of the pre-study measures of innate immune function (all P>0.4) or 
inflammation (all P>0.2). 
 
Plasma quercetin 
 Plasma quercetin increased significantly above placebo levels after twelve-week 
supplementation with 500 or 1000 mg/day aglycone quercetin (Group x time interaction 
effect, P<0.001) (Fig. 1). No significant correlations were found between plasma quercetin 
levels and dietary variables.  
 
Leukocyte subsets 
 The pattern of change over time was not significantly different between groups for 
total leukocytes (P=0.306), total lymphocytes (P=0.867) or neutrophil counts (P=0.193) 
(Table 2).  
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Plasma IL-6 and TNF-α 
 Twelve-week quercetin supplementation at 500 and 1000 mg/day had no effect on 
plasma concentrations of IL-6 (P=0.812) or TNF-α (P=0.208) (Table 2). 
 
GOBA and phagocytosis 
 The pattern of change over time for granulocyte phagocytosis (P=0.990) (Fig. 2) or 
oxidative burst activity (P=0.602) (Fig. 3) was not significantly different between groups. No 
correlations were found between any outcome measures and GOBA or phagocytosis. For all 
subjects combined, GOBA increased pre- to post-supplementation (P<0.001). 
 
Lymphocyte subsets 
 Circulating counts of NK, B, or T cells were not influenced by twelve-week 
supplementation with quercetin at 500 or 1000 mg/day (Table 3). 
 
NK cell activity 
 Pre- and post-supplementation data for killing of K562 target cells by NK cells 
showed no significant differences between groups across all E:T ratios (Table 4). The pattern 
of change over time for total NK cell cytotoxic activity was not different between treatment 
groups (P=0.696) (Fig. 4). Although NKCA tended to increase pre- to post-supplementation 
for all subjects combined, this apparent time effect did not reach significance (P=0.163). 
When pre- and post-study measures were averaged for all subjects combined (N=74), NKCA 
was correlated positively with self-reported physical fitness level (r=0.24, P=0.032) and 
negatively with BMI (r=-0.25, P=0.035) and body fat percentage (r=-0.38, P=0.001) (Fig. 5). 
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DISCUSSION 
 
 This is the first human clinical trial to investigate the long-term effects of aglycone 
quercetin supplementation on measures of innate immune function and inflammation in 
subjects recruited from the community. Subjects tended to be overweight individuals (mean 
BMI greater than 25.0 kg/m
2
) with mean pre-study plasma IL-6 and TNF-α concentrations 
that were slightly elevated compared to values reported for lean, healthy women in other 
studies (55, 56). The data indicate that twelve-week supplementation with 500 or 1000 
mg/day quercetin was not associated with changes in NKCA, GOBA, phagocytosis, or 
plasma concentration of IL-6 and TNF-α in this population.  
 Quercetin is a powerful antioxidant (6) that exerts in vitro anti-inflammatory effects 
through the inhibition of NF-κB signaling in a variety of cells including macrophages and 
peripheral blood mononuclear cells (8, 9). It was expected, therefore, that long-term 
quercetin supplementation would decrease circulating levels of IL-6 and TNF-α; however, 
quercetin had no effect on these markers of inflammation in the present study. Likewise, 
quercetin supplementation had no effect on NKCA, GOBA, or phagocytosis. A moderate 
time effect was noted for GOBA, highlighting the importance of seasonal effects on 
measures of immune function. The post-supplementation blood draw was in November, 
twelve weeks after the August pre-supplementation blood draw. Similar circannual rhythms 
in immune function have been observed in previous studies performed by our lab (57, 58). 
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Nonetheless, the pattern of change over time was not significantly different between 
treatment groups for any of the outcome measures in this study. 
 With regard to NKCA, GOBA, and granulocyte phagocytosis, the present findings are 
consistent with studies previously conducted in our lab investigating the effects of short-term 
quercetin supplementation on similar measures of innate immune function in athletes (46, 
48), but they are contrary to the results of quercetin studies utilizing rodent models and in 
vitro study designs (25, 27, 28). However, these human and animal studies may not be 
comparable for a number of reasons. For example, the Exon et al. (28) study used a larger 
dosage of quercetin (100 mg/kg) compared to the present study, which supplemented with 
average daily doses of 7 and 14 mg/kg quercetin for Q-500 and Q-1000. The dosages used in 
the Yu et al. (27) study were smaller (2 and 4 mg/kg), but the relevance of their results is 
confounded by the lack of a quercetin-treated group not injected with WEHI-3 cells. Possible 
species-dependent variations in phase II metabolism call into question the applicability of 
these animal study data to humans (59); furthermore, because of its metabolic transformation, 
quercetin circulates in the body and accumulates in tissues in forms that are quite different 
from those used in most in vitro studies (60).  
 Aglycone quercetin supplementation may lack an anti-inflammatory or 
immunomodulatory effect in humans due to either its reduced bioavailability or its metabolic 
transformation in vivo. Quercetin is found in fruits and vegetables in a water-soluble form in 
which the quercetin molecule is conjugated to a sugar moiety (2). The in vitro study 
conducted by Akbay et al. showed that neutrophil oxidative burst was increased by 
incubation with quercetin in such a glycosylated form (25). However, when quercetin is 
consumed, the sugar is cleaved off in the small intestine, allowing the lipid-soluble aglycone 
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form of quercetin to diffuse into the cells lining the intestinal wall (61). Quercetin in this 
aglycone form was used in the anti-inflammatory in vitro studies performed by Cho et al. 
(34), Nair et al. (9), and Min et al (35). During phase II metabolism in the liver, however, 
aglycone quercetin is either methylated, sulphated, or glucuronidated. Quercetin 
predominately circulates in the bloodstream in these conjugate forms, which differ not only 
from aglycone quercetin, but also from the glycosylated forms found in plant foods. 
Relatively few studies have examined the bioactivity of quercetin conjugates (60) and further 
work in this area is indicated. 
 Recent evidence in a murine model suggests that variation in apoE genotype may 
alter responsiveness to flavonoid supplementation. Boesch-Saadatmandi et al. (62) fed apoE3 
and apoE4 transgenic mice 400 mg/kg quercetin per day for six weeks and found that the 
quercetin-associated reduction in TNF-α production was significantly greater in mice with 
the apoE3 genotype. The Boesch-Saadatmandi et al. study assessed TNF-α production in 
whole blood stimulated ex vivo with lipopolysaccharide; thus their results are indicative of 
the effects of quercetin supplementation on inflammatory responses rather than on basal 
expression of TNF-α. Data regarding the effects of apoE genotype on responsiveness to 
quercetin supplementation in humans are limited. Egert et al. (63) assessed plasma TNF-α 
concentration after six weeks’ supplementation with 150 mg/day quercetin in obese and 
overweight human subjects, and found quercetin’s influence on serum HDL concentration 
and systolic blood pressure were dependent on apoE genotype, although no effect with TNF-
α was found. Future studies correlating apoE genotype with subject responsiveness to 
quercetin supplementation would be useful.  
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 Despite its known anti-inflammatory properties, the present study did not find a 
quercetin-related effect on circulating levels of IL-6 and TNF-α. It should be noted that, 
although the mean plasma TNF-α and IL-6 levels of subjects in this study were slightly 
elevated compared to those reported for lean females in other studies (55, 56), they fell 
within the normal ranges for adult females (64). It is possible that the lack of quercetin-
related effect on inflammation reported in the present study may be because these subjects 
were already within normal limits with regard to the outcome measures. Future studies 
comparing the effects of quercetin supplementation on inflammatory status in normal, 
overweight, and obese subjects would be of value. 
 While supplementation with aglycone quercetin appears to have no significant effect 
on inflammation, basal NKCA, or granulocyte function in humans, quercetin may exhibit an 
immunomodulatory and anti-inflammatory effect when ingested in other forms or in 
combination with other flavonoids. A recent human study found that four weeks 
supplementation with a fermented food rich in quercetin and other flavonoids significantly 
increased activation of NK cell cytotoxicity in response to IL-2 stimulation, but did not 
influence basal (non-stimulated) NKCA (65). Supplementation with polyphenol-rich cereal 
fractions has been shown to increase basal NKCA in prematurely aging mice, in addition to 
augmenting macrophage phagocytosis and ROS production (66). Our lab recently found that 
a two-week supplementation with a combination of quercetin, epigallocatechin 3-gallate 
(EGCG), isoquercetin, and omega-3 polyunsaturated fatty acids (N3-PUFAs) increased 
GOBA and decreased post-exercise plasma concentration of IL-6 (51). Future research will 
examine the combined supplements’ potential effects on NKCA and granulocyte 
phagocytosis. It may also be helpful to investigate whether IL-2-stimulated NK cell cytotoxic 
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activity in humans is affected by quercetin supplementation, alone or in combination with 
other flavonoids. In addition to studying quercetin’s effects on circulating levels of 
inflammatory markers, future studies may also assess inflammatory responsiveness using ex 
vivo stimulation of cells. 
 In the present study, we found that total NK cell cytotoxic activity was related 
inversely to BMI and body fat percentage, and positively with self-reported fitness level. 
These findings are consistent with previous studies linking NK cell function with physical 
fitness and healthy lifestyles (67, 68). A cross-sectional comparison between marathon 
runners and sedentary controls found that the marathoners had significantly greater NKCA 
than the controls, and that percent body fat was negatively correlated with NKCA for all 
subjects combined (67). In addition to physical exercise, other lifestyle factors such as not 
smoking and eating a balanced diet have been associated with elevated numbers of NK cells 
and enhanced NKCA, possibly due to an increased percentage of NK cells expressing 
perforin, granulysin, and granzymes A and B in subjects with good health practices (68). 
This suggests that optimization of NK cell function can be achieved through the maintenance 
of a healthy lifestyle. 
 In summary, twelve-week aglycone quercetin supplementation in doses of 500 and 
1000 mg/day had no effect on leukocyte subset counts, plasma IL-6 or TNF-α concentration, 
NKCA, GOBA, or granulocyte phagocytosis relative to placebo. A growing body of 
evidence indicates that a mixed flavonoid approach to modifying innate immunity is more 
effective than supplementation with a pure flavonoid such as aglycone quercetin. In athletes, 
a quercetin supplement combined with EGCG, isoquercetin, and N3-PUFAs significantly 
reduced post-exercise inflammation and augmented neutrophil function (51). Future research 
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will determine if the immunomodulatory effects of quercetin can be enhanced through the 
addition of other flavonoids (e.g., EGCG) or food components. 
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TABLE 1.  Subject characteristics (N=120, females, ages 30-79 years)
1
. 
 
 Placebo (N=42)  Q-500 (N=38)  Q-1000 (N=40)  F-Probability 
Age (y) 47.0 ± 1.1  45.4 ± 1.1  47.4 ± 1.3  0.459 
Height (m) 1.65 ± 0.01  1.64 ± 0.01  1.64 ± 0.01  0.940 
Weight (kg) 72.2 ± 2.9  71.3 ± 2.5  71.7 ± 3.4  0.979 
BMI (kg/m
2
) 26.6 ± 1.0  26.4 ± 0.9  26.6 ± 1.2  0.994 
Body fat (%) 34.5 ± 1.7  35.3 ± 1.5  34.3 ± 1.6  0.896 
 
1
 Data are presented as mean ± SEM. 
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TABLE 2.  Blood leukocyte subset cell counts and plasma inflammatory markers, at baseline 
and after twelve-week supplementation with quercetin at 500 or 1000 mg/day compared to 
placebo
1, 2
.  
 
      
Placebo 
(N=42) 
 
Q-500 
(N=38) 
 
Q-1000 
(N=40) 
 
Interaction 
P-value 
Leukocytes (10
9
/l)  
    Pre-study 5.91 ± 0.34 
 
5.80 ± 0.23 
 
5.78 ± 0.26  
0.306 
    Post-study 5.75 ± 0.29 5.94 ± 0.25 5.98 ± 0.31  
Neutrophils (10
9
/l)  
    Pre-study 3.41 ± 0.24 
 
3.50 ± 0.19 
 
3.21 ± 0.20  
0.193 
    Post-study 3.28 ± 0.21 3.63 ± 0.20 3.48 ± 0.24  
Lymphocytes (10
9
/l)  
    Pre-study 1.81 ± 0.09 
 
1.71 ± 0.07 
 
1.87 ± 0.09  
0.867 
    Post-study 1.81 ± 0.09 1.71 ± 0.08 1.84 ± 0.10  
IL-6 (pg/ml)  
    Pre-study 1.72 ± 0.18 
 
1.64 ± 0.19 
 
2.38 ± 0.78  
0.812 
    Post-study 1.76 ± 0.20 1.84 ± 0.25 2.58 ± 0.96  
TNF-α (pg/ml)  
    Pre-study 1.19 ± 0.10 
 
1.59 ± 0.22 
 
1.22 ± 0.17  
0.208 
    Post-study 1.24 ± 0.10 1.39 ± 0.19 1.24 ± 0.17  
 
1
 Pre- and post-study blood samples were obtained from all subjects (N=120) after an eight-hour fast.  
2
 Data are presented as mean ± SEM. 
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TABLE 3.  Blood lymphocyte subset cell counts for subjects with NKCA data (N=74), at 
baseline and after twelve-week supplementation with quercetin at 500 or 1000 mg/day 
compared to placebo
1,2
.  
 
 
1
 Pre- and post-study blood samples were analyzed for lymphocyte subsets using flow cytometry. 
2
 Data are presented as mean ± SEM. 
 
  
Placebo 
(N=26) 
 
Q-500 
(N=24) 
 
Q-1000 
(N=24) 
 Interaction 
P-value 
T cells (10
9
/l)         
 
 
    Pre-study 1.42 ± 0.08  1.33 ± 0.09  1.47 ± 0.08  
0.999 
    Post-study 1.41 ± 0.09  1.32 ± 0.09  1.46 ± 0.10  
B cells (10
9
/l)         
 
 
    Pre-study 0.24 ± 0.03  0.22 ± 0.02  0.23 ± 0.03  
0.603 
    Post-study 0.25 ± 0.02  0.22 ± 0.02  0.25 ± 0.04  
NK cells (10
9
/l)         
 
 
    Pre-study 0.20 ± 0.02  0.16 ± 0.02  0.18 ± 0.02  
0.885 
    Post-study 0.19 ± 0.02  0.15 ± 0.02  0.18 ± 0.02  
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TABLE 4.  NK cell activity, pre- and post- twelve-week supplementation with 500 or 1000 
mg/day quercetin compared to placebo, expressed as percent non-viable (%NV) target cells 
at four effector-to-target (E:T) cell ratios
1
.  
 
   E:T ratio 
Placebo 
(N=26) 
 
Q-500 
(N=24) 
 
Q-1000 
(N=24) 
 
Interaction 
P-value 
60:1 (%NV)  
    Pre-study 43.5 ± 3.4 
 
36.6 ± 3.3 
 
40.8 ± 2.8  
0.582 
    Post-study 47.2 ± 3.1 44.0 ± 3.6 49.1 ± 3.2  
30:1 (%NV)  
    Pre-study 37.9 ± 3.0 
 
32.3 ± 3.3 
 
35.6 ± 2.8  
0.659 
    Post-study 42.7 ± 3.0 37.5 ± 3.4 43.6 ± 3.3  
15:1 (%NV)  
    Pre-study 29.2 ± 2.5 
 
24.3 ± 3.0 
 
28.3 ± 2.9  
0.943 
    Post-study 32.6 ± 2.6 27.8 ± 2.8 32.6 ± 3.0  
7.5:1 (%NV)  
    Pre-study 19.9 ± 1.8 
 
17.0 ± 2.3 
 
20.1 ± 2.5  
0.950 
    Post-study 22.6 ± 1.9 19.8 ± 2.2 22.2 ± 2.4  
 
1
 NK cells (effectors) were incubated with K562 cells (targets) and analyzed by flow cytometry for 74 
subjects; the percentage of target cells that were killed due to NKCA at each E:T ratio is presented 
here as mean ± SEM. 
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FIGURE 1.  Plasma quercetin levels in response to twelve-week supplementation with 500 
or 1000 mg/day quercetin compared to placebo (N=120). Group x time interaction P<0.001.  
* P≤0.05, change from pre-study compared to placebo. 
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FIGURE 2.  Granulocyte phagocytosis of FITC-labeled S. aureus pre- and post-twelve week 
supplementation with 500 or 1000 mg/day quercetin compared to placebo (N=64). Data are 
expressed as shifts in mean FITC fluorescence from 4°C to 37°C. Group x time interaction 
P=0.990. 
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FIGURE 3.  Granulocyte oxidative burst activity following incubation with S. aureus pre- 
and post-twelve week supplementation with 500 or 1000 mg/day quercetin compared to 
placebo (N=64). Data are expressed as shifts in mean ethidium bromide fluorescence from 
4°C to 37°C. Group x time interaction P=0.602.
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FIGURE 4.  NK cell activity pre- and post-twelve week supplementation with 500 or 1000 
mg/day quercetin compared to placebo (N=74). NKCA is expressed as the number of lytic 
units contained in 10
7
 cells, where a lytic unit is defined as the number of NK cells required 
to kill 20% of 5000 K562 target cells. Group x time interaction P=0.696.  
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FIGURE 5.  Relationship between body fat percentage and NKCA of human subjects         
(r=-0.38, P=0.001). Data points average pre- and post-study measures for all subjects with 
NKCA data (N=74).  
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